These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 34911637)

  • 1. Quantitative SPECT/CT for Dosimetry of Peptide Receptor Radionuclide Therapy.
    Kennedy J; Chicheportiche A; Keidar Z
    Semin Nucl Med; 2022 Mar; 52(2):229-242. PubMed ID: 34911637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
    Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
    J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiopharmaceuticals used for diagnosis and therapy of NETs.
    Papachristou M
    Hell J Nucl Med; 2023; 26 Suppl():19-20. PubMed ID: 37658556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor imaging and therapy using radiolabeled somatostatin analogues.
    de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
    Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.
    Kulkarni HR; Baum RP
    PET Clin; 2014 Jan; 9(1):83-90. PubMed ID: 25029937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide receptor radionuclide therapy with somatostatin analogues in neuroendocrine tumors.
    Giovacchini G; Nicolas G; Forrer F
    Anticancer Agents Med Chem; 2012 Jun; 12(5):526-42. PubMed ID: 22292758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
    Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The predictive value of pretherapy [
    Akhavanallaf A; Peterson AB; Fitzpatrick K; Roseland M; Wong KK; El-Naqa I; Zaidi H; Dewaraja YK
    Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):2984-2996. PubMed ID: 37171633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of
    Krebs S; O'Donoghue JA; Biegel E; Beattie BJ; Reidy D; Lyashchenko SK; Lewis JS; Bodei L; Weber WA; Pandit-Taskar N
    Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3047-3057. PubMed ID: 32378020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lutetium-labelled peptides for therapy of neuroendocrine tumours.
    Kam BL; Teunissen JJ; Krenning EP; de Herder WW; Khan S; van Vliet EI; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1(Suppl 1):S103-12. PubMed ID: 22388631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application and Dosimetric Requirements for Gallium-68-labeled Somatostatin Analogues in Targeted Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors.
    Taïeb D; Garrigue P; Bardiès M; Abdullah AE; Pacak K
    PET Clin; 2015 Oct; 10(4):477-86. PubMed ID: 26384594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
    Harris PE; Zhernosekov K
    Front Endocrinol (Lausanne); 2022; 13():941832. PubMed ID: 36387893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-specific dosimetry in peptide receptor radionuclide therapy: a clinical review.
    Chalkia MT; Stefanoyiannis AP; Chatziioannou SN; Round WH; Efstathopoulos EP; Nikiforidis GC
    Australas Phys Eng Sci Med; 2015 Mar; 38(1):7-22. PubMed ID: 25427548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.
    Teunissen JJ; Kwekkeboom DJ; Valkema R; Krenning EP
    Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S27-51. PubMed ID: 22005114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, preparation and biological evaluation of a
    Behnammanesh H; Jokar S; Erfani M; Geramifar P; Sabzevari O; Amini M; Mazidi SM; Hajiramezanali M; Beiki D
    Bioorg Chem; 2020 Jan; 94():103381. PubMed ID: 31662215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Value of
    Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
    J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide Receptor Radionuclide Therapy with
    Cullinane C; Jeffery CM; Roselt PD; van Dam EM; Jackson S; Kuan K; Jackson P; Binns D; van Zuylekom J; Harris MJ; Hicks RJ; Donnelly PS
    J Nucl Med; 2020 Dec; 61(12):1800-1805. PubMed ID: 32414949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
    Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
    J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 177 Lu-DOTATATE PRRT for Multiple Unusual Metastatic Sites in Neuroendocrine Tumor.
    Parghane RV; Basu S
    Clin Nucl Med; 2022 Oct; 47(10):874-875. PubMed ID: 35353741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
    Kaltsas GA; Papadogias D; Makras P; Grossman AB
    Endocr Relat Cancer; 2005 Dec; 12(4):683-99. PubMed ID: 16322317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.